

---

## Table 2: Total number of STI diagnoses & other episodes of care seen at genitourinary medicine clinics in England: 2001 - 2010



Data are presented by SHA, gender & sexual orientation

---

### Notes on using these tables:

Numbers of diagnoses are adjusted for missing clinic data  
Data on unknown gender are included in the 'Total'

An improved STI surveillance system (GUMCAD) was introduced in England in 2009. Unlike the KC60 return, duplicate records in GUMCAD can be identified and removed resulting in a slight reduction in the number of diagnoses reported. England (SHA) data from 2000-2008 have therefore been statistically adjusted to enable fair comparisons of STI diagnoses over time.

### Definitions of data totals:

Total new STI diagnoses:	}	Refer to 'Code Groups' for conditions included
Total other STI diagnoses:		
Total other GUM clinic diagnoses:		
Total services provided:		

### Data source:

England:           GUM clinic KC60 returns (2001-2008)  
                      GUM clinic GUMCAD returns (2009-2010)

### Data supplied by:

Health Protection Agency, Health Protection Services Colindale

---

### Data prepared by:

HIV and Sexually Transmitted Infections Department  
Health Protection Agency  
Health Protection Services Colindale  
61 Colindale Avenue  
London  
NW9 5EQ

Tel. 020-8200-6868

Email: [hiv/sti@hpa.org.uk](mailto:hiv/sti@hpa.org.uk)

Website: [www.hpa.org.uk](http://www.hpa.org.uk)

---

**Table 2: Total number of STI diagnoses & other episodes of care seen  
at genitourinary medicine clinics in England: 2001 - 2010**  
Data are presented by SHA, gender & sexual orientation

---



**Data tables**

England 2 a:

Code groups: Definitions of conditions presented

---

**Further Information**

**England**

Data on selected diagnoses, 1971 to 2010, are available upon request

HPA Health Protection Services Colindale

Contact: Geraldine Leong

Tel: +44 (0)20 8200 6868

Email: [geraldine.leong@hpa.org.uk](mailto:geraldine.leong@hpa.org.uk)

Web: [www.hpa.org.uk](http://www.hpa.org.uk)



## 2 a: England

### Number of new STI episodes seen at genitourinary medicine clinics by gender: 2001 - 2010

Diagnoses and/or treatment of infection or disease			2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
A1,A2	Primary and secondary infectious syphilis	Male (all)	586	997	1,278	1,676	2,041	2,040	2,006	1,774	1,851	1,671
		-of which MSM	329	574	710	847	1,195	1,163	1,173	989	1,229	1,070
		Female	93	128	171	251	329	263	267	224	188	172
		<b>Total</b>	<b>679</b>	<b>1,125</b>	<b>1,449</b>	<b>1,927</b>	<b>2,370</b>	<b>2,303</b>	<b>2,273</b>	<b>1,998</b>	<b>2,048</b>	<b>1,858</b>
A3	Early latent syphilis (first 2 years)	Male (all)	260	318	410	507	642	643	777	734	646	647
		-of which MSM	110	170	188	265	374	397	437	398	422	420
		Female	96	117	146	192	174	170	157	142	152	119
		<b>Total</b>	<b>356</b>	<b>435</b>	<b>556</b>	<b>699</b>	<b>816</b>	<b>813</b>	<b>934</b>	<b>876</b>	<b>798</b>	<b>766</b>
A4,A5,A6	Other acquired syphilis	Male (all)	803	822	967	1,056	1,030	1,038	1,018	953	988	1,050
		-of which MSM	117	126	150	150	172	232	210	244	270	316
		Female	604	708	763	823	802	685	770	705	669	671
		<b>Total</b>	<b>1,407</b>	<b>1,530</b>	<b>1,730</b>	<b>1,879</b>	<b>1,832</b>	<b>1,723</b>	<b>1,788</b>	<b>1,658</b>	<b>1,658</b>	<b>1,730</b>
A7	Congenital syphilis, aged under 2	Male (all)	2	2	3	4	6	3	1	2	0	0
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	5	0	3	8	3	3	1	0	0
<b>Total</b>	<b>2</b>	<b>7</b>	<b>3</b>	<b>7</b>	<b>14</b>	<b>6</b>	<b>4</b>	<b>3</b>	<b>0</b>	<b>0</b>		
A8	Congenital syphilis, aged 2 or over	Male (all)	3	5	1	5	9	4	3	3	4	0
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	6	9	4	4	13	4	5	2	5	2
<b>Total</b>	<b>9</b>	<b>14</b>	<b>5</b>	<b>9</b>	<b>22</b>	<b>8</b>	<b>8</b>	<b>5</b>	<b>9</b>	<b>2</b>		
A9	Epidemiological treatment of suspected syphilis	Male (all)	61	155	252	362	481	646	735	803	918	899
		-of which MSM	23	80	146	207	280	409	462	457	612	564
		Female	30	48	65	88	121	123	154	135	146	140
		<b>Total</b>	<b>91</b>	<b>203</b>	<b>317</b>	<b>450</b>	<b>602</b>	<b>769</b>	<b>889</b>	<b>938</b>	<b>1,066</b>	<b>1,041</b>
B1,B2	Uncomplicated gonorrhoea	Male (all)	15,309	16,570	15,930	14,190	12,429	12,006	11,493	9,729	10,572	11,289
		-of which MSM	3,333	3,184	3,527	3,491	3,788	3,928	3,228	2,597	3,379	4,503
		Female	6,550	7,205	7,032	6,108	4,899	4,885	5,299	4,940	5,004	4,825
		<b>Total</b>	<b>21,859</b>	<b>23,775</b>	<b>22,962</b>	<b>20,298</b>	<b>17,328</b>	<b>16,891</b>	<b>16,792</b>	<b>14,669</b>	<b>15,606</b>	<b>16,145</b>
B3	Gonococcal ophthalmia neonatorum	Male (all)	7	8	7	10	9	19	12	16	20	15
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	9	9	14	14	80	8	16	21	15	16
<b>Total</b>	<b>16</b>	<b>17</b>	<b>21</b>	<b>24</b>	<b>89</b>	<b>27</b>	<b>28</b>	<b>37</b>	<b>35</b>	<b>31</b>		
B4	Epidemiological treatment of suspected gonorrhoea	Male (all)	2,562	2,985	3,273	3,417	3,492	3,699	4,190	4,348	4,597	4,918
		-of which MSM	809	872	1,070	1,094	1,224	1,325	1,317	1,183	1,494	1,760
		Female	2,541	2,918	3,108	3,037	3,051	2,896	3,226	3,422	3,022	2,762
		<b>Total</b>	<b>5,103</b>	<b>5,903</b>	<b>6,381</b>	<b>6,454</b>	<b>6,543</b>	<b>6,595</b>	<b>7,416</b>	<b>7,770</b>	<b>7,633</b>	<b>7,694</b>
B5	Complicated gonococcal infection including PID and epididymitis	Male (all)	89	99	93	128	95	81	92	91	123	150
		-of which MSM	13	24	10	18	29	17	17	18	23	63
		Female	250	249	291	243	209	219	235	225	249	236
		<b>Total</b>	<b>339</b>	<b>348</b>	<b>384</b>	<b>371</b>	<b>304</b>	<b>300</b>	<b>327</b>	<b>316</b>	<b>372</b>	<b>386</b>

**England: Number of new STI episodes by gender: 2001 - 2010 (continued)**

			2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
C1,C2,C3	Chancroid/LGV/Donovanosis	Male (all)	29	34	59	85	255	209	250	265	238	405	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	33	37	75	63	57	66	128	83	62	73	
		<b>Total</b>	<b>62</b>	<b>71</b>	<b>134</b>	<b>148</b>	<b>312</b>	<b>275</b>	<b>378</b>	<b>348</b>	<b>302</b>	<b>479</b>	
C4A,C4C	Uncomplicated genital chlamydial infection	Male (all)	29,071	33,774	37,397	42,049	44,604	48,301	52,791	53,697	49,276	47,127	
		-of which MSM	1,265	1,328	1,616	1,676	2,116	2,626	2,918	3,569	4,084	4,975	
		Female	37,810	42,882	46,557	49,297	49,816	49,209	52,496	53,426	47,475	43,843	
		<b>Total</b>	<b>66,881</b>	<b>76,656</b>	<b>83,954</b>	<b>91,346</b>	<b>94,420</b>	<b>97,510</b>	<b>105,287</b>	<b>107,123</b>	<b>96,869</b>	<b>91,075</b>	
C4B	Complicated genital chlamydial infection - including PID and epididymitis	Male (all)	525	550	615	631	701	755	775	853	833	773	
		-of which MSM	34	31	50	43	67	67	64	89	103	98	
		Female	2,005	2,065	2,026	2,239	2,170	2,112	2,445	2,446	2,278	2,083	
		<b>Total</b>	<b>2,530</b>	<b>2,615</b>	<b>2,641</b>	<b>2,870</b>	<b>2,871</b>	<b>2,867</b>	<b>3,220</b>	<b>3,299</b>	<b>3,113</b>	<b>2,859</b>	
C4D	Chlamydial ophthalmia neonatorum	Male (all)	15	15	18	41	15	13	13	17	13	8	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	28	25	25	34	22	19	8	16	13	10	
		<b>Total</b>	<b>43</b>	<b>40</b>	<b>43</b>	<b>75</b>	<b>37</b>	<b>32</b>	<b>21</b>	<b>33</b>	<b>26</b>	<b>18</b>	
C4E	Epidemiological treatment of suspected genital chlamydial infection	Male (all)	17,238	21,365	22,384	24,221	25,820	25,043	28,453	29,469	29,046	28,309	
		-of which MSM	617	1,025	1,272	1,354	1,614	1,903	2,140	2,401	2,695	3,121	
		Female	12,015	14,110	14,552	16,563	18,384	18,496	20,322	21,656	20,251	18,576	
		<b>Total</b>	<b>29,253</b>	<b>35,475</b>	<b>36,936</b>	<b>40,784</b>	<b>44,204</b>	<b>43,539</b>	<b>48,775</b>	<b>51,125</b>	<b>49,348</b>	<b>46,936</b>	
C4H*	Uncomplicated non-gonococcal/non-specific urethritis in males, or treatment of mucopurulent cervicitis in females	Male (all)	58,216	60,753	65,909	68,556	69,043	68,288	66,185	61,861	57,032	52,199	
		-of which MSM	4,454	4,365	4,884	4,935	5,081	5,592	5,044	4,969	4,911	4,836	
		Female	0	0	6,518	7,305	7,265	6,616	6,308	6,398	6,108	6,125	
		<b>Total</b>	<b>58,216</b>	<b>60,753</b>	<b>72,427</b>	<b>75,861</b>	<b>76,308</b>	<b>74,904</b>	<b>72,493</b>	<b>68,259</b>	<b>63,217</b>	<b>58,417</b>	
C4I	Epidemiological treatment of NSGI	Male (all)	5,872	5,864	5,924	6,176	5,725	5,590	5,896	5,870	5,986	5,874	
		-of which MSM	671	602	730	788	737	815	716	670	682	676	
		Female	19,446	18,431	16,822	17,031	16,855	15,895	15,934	14,418	13,276	11,659	
		<b>Total</b>	<b>25,318</b>	<b>24,295</b>	<b>22,746</b>	<b>23,207</b>	<b>22,580</b>	<b>21,485</b>	<b>21,830</b>	<b>20,288</b>	<b>19,281</b>	<b>17,538</b>	
C5	Complicated infection (non-chlamydial/non-gonococcal) - including PID and epididymitis	Male (all)	3,646	3,807	3,887	4,289	4,940	4,648	5,101	5,704	6,380	6,495	
		-of which MSM	233	213	235	271	334	321	340	493	598	555	
		Female	10,730	11,107	10,544	12,270	11,740	12,164	13,934	14,878	15,568	15,039	
		<b>Total</b>	<b>14,376</b>	<b>14,914</b>	<b>14,431</b>	<b>16,559</b>	<b>16,680</b>	<b>16,812</b>	<b>19,035</b>	<b>20,582</b>	<b>21,971</b>	<b>21,566</b>	
C6A	Trichomoniasis	Male (all)	708	550	277	290	320	306	376	334	357	349	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	6,093	6,430	6,038	5,750	4,932	5,028	5,169	5,215	4,532	4,576	
		<b>Total</b>	<b>6,801</b>	<b>6,980</b>	<b>6,315</b>	<b>6,040</b>	<b>5,252</b>	<b>5,334</b>	<b>5,545</b>	<b>5,549</b>	<b>4,900</b>	<b>4,930</b>	
C6B	Anaerobic/Bacterial vaginosis & anaerobic balanitis	Male (all)	1,373	1,372	1,423	1,406	1,453	1,615	1,641	1,870	1,875	2,077	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	63,720	69,644	70,647	68,187	69,452	72,204	84,201	90,198	92,703	93,306	
		<b>Total</b>	<b>65,093</b>	<b>71,016</b>	<b>72,070</b>	<b>69,593</b>	<b>70,905</b>	<b>73,819</b>	<b>85,842</b>	<b>92,068</b>	<b>94,823</b>	<b>95,628</b>	
C6C	Other vaginosis/vaginitis/balanitis	Male (all)	11,586	11,280	11,431	11,275	10,737	10,531	12,278	13,062	12,535	11,770	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	6,518	5,481	5,193	5,603	4,691	4,159	4,449	5,025	4,283	3,689	
		<b>Total</b>	<b>18,104</b>	<b>16,761</b>	<b>16,624</b>	<b>16,878</b>	<b>15,428</b>	<b>14,690</b>	<b>16,727</b>	<b>18,087</b>	<b>16,888</b>	<b>15,503</b>	

**England: Number of new STI episodes by gender: 2001 - 2010 (continued)**

			2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
C7A	Anogenital candidosis	Male (all)	7,048	6,715	5,871	5,844	5,502	6,276	7,478	7,973	8,630	8,930	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	68,780	69,269	65,593	61,867	58,452	57,310	64,329	69,112	71,039	71,685	
	<b>Total</b>	<b>75,828</b>	<b>75,984</b>	<b>71,464</b>	<b>67,711</b>	<b>63,954</b>	<b>63,586</b>	<b>71,807</b>	<b>77,085</b>	<b>79,819</b>	<b>80,770</b>		
C7B	Epidemiological treatment of C6 & C7	Male (all)	3,687	4,128	4,215	4,148	4,327	4,111	4,626	4,848	4,983	4,376	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	6,599	6,599	6,981	7,824	7,223	7,147	7,922	8,777	8,000	7,086	
	<b>Total</b>	<b>10,286</b>	<b>10,727</b>	<b>11,196</b>	<b>11,972</b>	<b>11,550</b>	<b>11,258</b>	<b>12,548</b>	<b>13,625</b>	<b>12,996</b>	<b>11,475</b>		
C8,C9	Scabies/pediculosis pubis	Male (all)	4,110	3,536	3,008	2,383	1,858	1,832	1,746	1,714	1,770	1,677	
		-of which MSM	791	697	587	495	443	462	403	424	534	502	
		Female	933	694	497	390	300	255	269	240	237	224	
	<b>Total</b>	<b>5,043</b>	<b>4,230</b>	<b>3,505</b>	<b>2,773</b>	<b>2,158</b>	<b>2,087</b>	<b>2,015</b>	<b>1,954</b>	<b>2,008</b>	<b>1,903</b>		
C10A	Anogenital herpes simplex – first episode	Male (all)	6,411	6,445	6,369	6,356	6,730	7,456	9,055	10,104	10,824	11,584	
		-of which MSM	391	468	457	448	538	515	600	735	818	973	
		Female	10,395	10,814	10,534	10,338	10,649	11,798	14,432	15,990	16,703	18,090	
	<b>Total</b>	<b>16,806</b>	<b>17,259</b>	<b>16,903</b>	<b>16,694</b>	<b>17,379</b>	<b>19,254</b>	<b>23,487</b>	<b>26,094</b>	<b>27,564</b>	<b>29,703</b>		
C10B	Anogenital herpes simplex – recurrence	Male (all)	5,759	5,922	5,916	5,632	5,805	6,159	6,699	7,543	8,476	9,104	
		-of which MSM	364	357	421	397	458	471	510	618	675	741	
		Female	7,478	7,573	7,451	7,173	7,439	7,792	9,113	10,224	11,743	12,497	
	<b>Total</b>	<b>13,237</b>	<b>13,495</b>	<b>13,367</b>	<b>12,805</b>	<b>13,244</b>	<b>13,951</b>	<b>15,812</b>	<b>17,767</b>	<b>20,268</b>	<b>21,669</b>		
C11A	Anogenital warts – first episode	Male (all)	32,285	33,542	34,198	35,972	35,975	37,021	39,723	41,094	41,934	40,953	
		-of which MSM	1,744	1,931	2,074	2,003	2,225	2,280	2,339	2,488	2,557	2,528	
		Female	29,220	29,440	30,121	31,279	31,877	32,679	35,549	37,062	35,904	34,582	
	<b>Total</b>	<b>61,505</b>	<b>62,982</b>	<b>64,319</b>	<b>67,251</b>	<b>67,852</b>	<b>69,700</b>	<b>75,272</b>	<b>78,156</b>	<b>77,900</b>	<b>75,615</b>		
C11B	Anogenital warts – recurrence	Male (all)	21,122	20,632	20,393	20,781	21,830	23,056	25,446	26,484	26,008	25,644	
		-of which MSM	1,259	1,271	1,419	1,469	1,419	1,591	1,784	1,743	1,793	1,845	
		Female	11,405	11,371	11,705	11,987	12,848	14,049	15,851	16,810	15,958	15,570	
	<b>Total</b>	<b>32,527</b>	<b>32,003</b>	<b>32,098</b>	<b>32,768</b>	<b>34,678</b>	<b>37,105</b>	<b>41,297</b>	<b>43,294</b>	<b>42,026</b>	<b>41,314</b>		
C11C	Anogenital warts – re-registered cases	Male (all)	8,066	7,595	7,918	7,636	7,899	8,173	8,182	8,430	7,748	7,360	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	6,462	5,882	5,979	5,823	6,170	6,090	6,038	6,008	5,391	4,895	
	<b>Total</b>	<b>14,528</b>	<b>13,477</b>	<b>13,897</b>	<b>13,459</b>	<b>14,069</b>	<b>14,263</b>	<b>14,220</b>	<b>14,438</b>	<b>13,154</b>	<b>12,278</b>		
C12	Molluscum contagiosum	Male (all)	5,128	5,697	6,391	7,409	8,167	8,877	9,724	10,188	9,644	8,731	
		-of which MSM	204	189	224	232	260	279	297	357	307	270	
		Female	2,768	2,993	3,213	3,596	3,920	4,161	4,453	4,499	3,875	3,742	
	<b>Total</b>	<b>7,896</b>	<b>8,690</b>	<b>9,604</b>	<b>11,005</b>	<b>12,087</b>	<b>13,038</b>	<b>14,177</b>	<b>14,687</b>	<b>13,534</b>	<b>12,492</b>		
C13	Antigen positive viral hepatitis B	Male (all)	704	931	-	-	-	-	-	-	-	-	
		-of which MSM	155	195	-	-	-	-	-	-	-	-	
		Female	352	472	-	-	-	-	-	-	-	-	
	<b>Total</b>	<b>1,056</b>	<b>1,403</b>	-	-	-	-	-	-	-	-		
C13A*	Viral hepatitis B (HbsAg positive): first diagnosis**	Male (all)	-	-	588	642	626	607	658	731	818	743	
		-of which MSM	-	-	109	86	88	59	56	77	85	89	
		Female	-	-	264	319	317	333	344	389	412	367	
	<b>Total</b>	-	-	<b>852</b>	<b>961</b>	<b>943</b>	<b>940</b>	<b>1,002</b>	<b>1,120</b>	<b>1,232</b>	<b>1,111</b>		

**England: Number of new STI episodes by gender: 2001 - 2010 (continued)**

			2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
C13B*	**number of which were acute viral hepatitis B	Male (all)	-	-	46	53	44	40	42	62	51	61
		-of which MSM	-	-	14	19	14	7	5	19	15	14
		Female	-	-	10	12	25	26	20	16	29	22
		<b>Total</b>	-	-	56	65	69	66	62	78	80	83
C13C*	Viral hepatitis B: subsequent presentation	Male (all)	-	-	327	442	400	412	468	569	637	528
		-of which MSM	-	-	117	195	196	218	140	204	171	139
		Female	-	-	144	166	144	185	185	253	299	307
		<b>Total</b>	-	-	471	608	544	597	653	822	940	835
C14*	Viral hepatitis C: fist diagnosis (previous to 2003 C14 was other viral hepatitis)	Male (all)	814	921	890	911	835	758	717	947	1,121	779
		-of which MSM	90	121	97	108	99	101	71	237	408	173
		Female	336	427	406	387	354	315	259	351	365	257
		<b>Total</b>	1,150	1,348	1,296	1,298	1,189	1,073	976	1,298	1,490	1,036
E1A	New HIV diagnosis - asymptomatic	Male (all)	1,514	2,109	2,444	2,555	2,631	2,450	3,061	2,731	2,585	2,605
		-of which MSM	676	677	1,002	1,103	1,193	1,124	1,245	1,171	1,478	1,371
		Female	1,014	1,807	1,946	1,906	1,878	1,556	1,999	1,511	1,261	1,106
		<b>Total</b>	2,528	3,916	4,390	4,461	4,509	4,006	5,060	4,242	3,848	3,714
E1B*	Asymptomatic HIV infection – subsequent presentation	Male (all)	8,375	10,058	-	-	-	-	-	-	-	-
		-of which MSM	0	0	-	-	-	-	-	-	-	-
		Female	3,792	5,532	-	-	-	-	-	-	-	-
		<b>Total</b>	12,167	15,590	-	-	-	-	-	-	-	-
E1BE2B*	Subsequent HIV presentation (not AIDS)	Male (all)	-	-	19,046	22,875	28,088	29,826	29,767	32,539	34,087	37,198
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	-	-	9,003	12,065	15,228	16,402	17,414	19,129	19,097	20,036
		<b>Total</b>	-	-	28,049	34,940	43,316	46,228	47,181	51,668	53,275	57,366
E2A	New HIV diagnosis: symptomatic (not AIDS)	Male (all)	607	701	626	632	697	580	452	542	467	481
		-of which MSM	286	231	249	236	240	211	134	190	217	203
		Female	307	420	416	362	422	335	288	314	262	240
		<b>Total</b>	914	1,121	1,042	994	1,119	915	740	856	729	722
E2B*	HIV infection with symptoms, not AIDS – subsequent presentation	Male (all)	9,139	9,265	-	-	-	-	-	-	-	-
		-of which MSM	0	0	-	-	-	-	-	-	-	-
		Female	2,623	3,310	-	-	-	-	-	-	-	-
		<b>Total</b>	11,762	12,575	-	-	-	-	-	-	-	-
E3A*	AIDS – first presentation	Male (all)	430	436	-	-	-	-	-	-	-	-
		-of which MSM	167	155	-	-	-	-	-	-	-	-
		Female	214	227	-	-	-	-	-	-	-	-
		<b>Total</b>	644	663	-	-	-	-	-	-	-	-
E3A1*	AIDS: first presentation - new HIV diagnosis	Male (all)	-	-	157	199	207	174	218	199	239	196
		-of which MSM	-	-	63	55	70	59	69	59	66	61
		Female	-	-	124	106	138	80	88	111	121	94
		<b>Total</b>	-	-	281	305	345	254	306	310	360	290
E3A2*	AIDS: first presentation - HIV diagnosed previously	Male (all)	-	-	225	149	155	152	107	115	74	63
		-of which MSM	-	-	89	71	58	80	46	60	39	24
		Female	-	-	126	61	69	67	48	49	24	38
		<b>Total</b>	-	-	351	210	224	219	155	164	98	101

**England: Number of new STI episodes by gender: 2001 - 2010 (continued)**

			2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
E3B	AIDS – subsequent presentation	Male (all)	4,781	5,391	6,697	7,289	8,309	8,362	8,026	8,448	8,152	8,259	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	1,416	1,785	2,739	3,011	3,494	3,664	3,809	4,011	3,876	4,072	
		<b>Total</b>	<b>6,197</b>	<b>7,176</b>	<b>9,436</b>	<b>10,300</b>	<b>11,803</b>	<b>12,026</b>	<b>11,835</b>	<b>12,459</b>	<b>12,029</b>	<b>12,331</b>	
D2A	Urinary tract infection	Male (all)	1,925	2,446	2,403	2,414	1,970	1,933	2,148	2,368	2,552	2,443	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	9,150	8,880	8,455	9,491	9,089	9,409	11,748	13,946	14,328	14,021	
		<b>Total</b>	<b>11,075</b>	<b>11,326</b>	<b>10,858</b>	<b>11,905</b>	<b>11,059</b>	<b>11,342</b>	<b>13,896</b>	<b>16,314</b>	<b>16,901</b>	<b>16,500</b>	
D2B	Other conditions requiring treatment at GUM clinic	Male (all)	49,645	52,013	58,139	58,702	60,864	62,021	71,120	80,616	84,059	87,548	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	49,411	49,654	48,206	49,764	50,901	51,669	58,166	65,616	73,228	75,984	
		<b>Total</b>	<b>99,056</b>	<b>101,667</b>	<b>106,345</b>	<b>108,466</b>	<b>111,765</b>	<b>113,690</b>	<b>129,286</b>	<b>146,232</b>	<b>157,507</b>	<b>163,757</b>	
D3	Other episodes not requiring treatment	Male (all)	125,321	141,931	133,675	160,847	189,379	208,127	236,455	265,196	278,265	303,424	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	131,498	146,874	135,640	158,894	191,100	207,497	244,488	273,384	280,324	301,935	
		<b>Total</b>	<b>256,819</b>	<b>288,805</b>	<b>269,315</b>	<b>319,741</b>	<b>380,479</b>	<b>415,624</b>	<b>480,943</b>	<b>538,580</b>	<b>559,333</b>	<b>606,182</b>	
P1A	HIV antibody test (no sexual health screen)	Male (all)	109,903	145,623	48,164	42,800	40,009	33,782	31,277	30,869	26,813	30,451	
		-of which MSM	15,980	18,223	8,154	7,418	7,756	7,281	6,725	4,757	7,568	9,730	
		Female	92,977	129,933	37,024	30,501	29,945	25,224	24,261	23,923	20,269	20,435	
		<b>Total</b>	<b>202,880</b>	<b>275,556</b>	<b>85,188</b>	<b>73,301</b>	<b>69,954</b>	<b>59,006</b>	<b>55,538</b>	<b>54,792</b>	<b>47,140</b>	<b>50,913</b>	
P1B	HIV antibody test offered and refused	Male (all)	19,265	42,360	95,065	116,282	113,294	107,708	111,942	116,257	115,478	113,117	
		-of which MSM	1,643	3,102	5,937	6,238	6,302	6,288	6,034	6,553	6,941	6,779	
		Female	19,130	47,485	109,531	133,491	131,821	127,902	141,056	153,260	158,182	162,318	
		<b>Total</b>	<b>38,395</b>	<b>89,845</b>	<b>204,596</b>	<b>249,773</b>	<b>245,115</b>	<b>235,610</b>	<b>252,998</b>	<b>269,517</b>	<b>273,968</b>	<b>275,570</b>	
P2	Hepatitis B vaccination	Male (all)	11,479	12,902	14,033	15,357	15,085	15,508	16,345	18,439	17,930	18,616	
		-of which MSM	5,652	6,387	7,590	8,071	8,189	8,090	8,014	8,481	9,240	9,603	
		Female	3,049	3,791	3,971	4,836	5,125	5,391	5,975	7,084	6,953	7,142	
		<b>Total</b>	<b>14,528</b>	<b>16,693</b>	<b>18,004</b>	<b>20,193</b>	<b>20,210</b>	<b>20,899</b>	<b>22,320</b>	<b>25,523</b>	<b>24,908</b>	<b>25,788</b>	
P3	Contraception (excluding condom provision)	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	33,646	31,444	32,774	33,858	34,680	37,987	45,488	53,213	62,740	77,673	
		<b>Total</b>	<b>33,646</b>	<b>31,444</b>	<b>32,774</b>	<b>33,858</b>	<b>34,680</b>	<b>37,987</b>	<b>45,488</b>	<b>53,213</b>	<b>62,740</b>	<b>77,673</b>	
P4A	Cervical cytology - minor abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	4,574	3,536	4,992	3,238	1,620	1,313	1,309	1,493	1,601	1,320	
		<b>Total</b>	<b>4,574</b>	<b>3,536</b>	<b>4,992</b>	<b>3,238</b>	<b>1,620</b>	<b>1,313</b>	<b>1,309</b>	<b>1,493</b>	<b>1,601</b>	<b>1,320</b>	

**England: Number of new STI episodes by gender: 2001 - 2010 (continued)**

			2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
P4B	Cervical cytology - major abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	988	724	877	767	372	282	248	331	282	202
		<b>Total</b>	<b>988</b>	<b>724</b>	<b>877</b>	<b>767</b>	<b>372</b>	<b>282</b>	<b>248</b>	<b>331</b>	<b>282</b>	<b>202</b>
S1*	Sexual health screen (no HIV antibody test)	Male (all)	-	-	141,976	143,006	136,577	131,824	135,379	133,994	129,759	128,040
		-of which MSM	-	-	9,684	9,836	10,776	11,977	11,627	12,126	14,302	16,022
		Female	-	-	176,335	174,395	168,840	161,169	172,285	177,389	171,669	171,120
		<b>Total</b>	-	-	<b>318,311</b>	<b>317,401</b>	<b>305,417</b>	<b>292,993</b>	<b>307,664</b>	<b>311,383</b>	<b>301,963</b>	<b>299,627</b>
S2*	HIV antibody test and sexual health screen	Male (all)	-	-	158,950	208,289	255,335	298,546	357,661	406,203	426,443	435,541
		-of which MSM	-	-	15,882	18,983	22,932	27,686	30,499	37,943	44,762	49,567
		Female	-	-	156,028	202,182	251,703	292,160	360,987	417,334	437,135	443,752
		<b>Total</b>	-	-	<b>314,978</b>	<b>410,471</b>	<b>507,038</b>	<b>590,706</b>	<b>718,648</b>	<b>823,537</b>	<b>864,749</b>	<b>880,741</b>
<b>Total new STI diagnoses (for GUM clinics only)</b>	Male (all)	158,494	169,482	179,048	187,907	191,335	195,667	203,825	201,614	194,771	187,332	
	-of which MSM	13,863	14,082	15,876	16,118	17,953	19,041	18,308	18,546	20,726	22,428	
	Female	108,297	116,388	126,249	131,695	130,775	131,596	143,516	147,704	139,979	135,169	
	<b>Total</b>	<b>266,791</b>	<b>285,870</b>	<b>305,297</b>	<b>319,602</b>	<b>322,110</b>	<b>327,263</b>	<b>347,341</b>	<b>349,318</b>	<b>335,139</b>	<b>322,920</b>	
<b>Total other STI diagnoses</b>	Male (all)	84,235	90,520	93,024	99,654	108,673	111,783	118,548	125,040	126,117	128,701	
	-of which MSM	4,027	4,488	5,297	5,530	5,962	6,826	7,185	7,376	8,260	9,047	
	Female	68,069	71,943	72,356	77,717	84,584	86,193	92,711	96,607	93,486	90,944	
	<b>Total</b>	<b>152,304</b>	<b>162,463</b>	<b>165,380</b>	<b>177,371</b>	<b>193,257</b>	<b>197,976</b>	<b>211,259</b>	<b>221,647</b>	<b>219,906</b>	<b>220,049</b>	
<b>Total other GUM clinic diagnoses</b>	Male (all)	76,782	79,806	85,333	85,837	86,758	88,304	101,176	113,046	117,261	119,255	
	-of which MSM	245	316	337	408	397	385	272	537	679	415	
	Female	210,428	214,686	211,768	207,625	202,640	204,352	233,180	255,507	266,569	268,246	
	<b>Total</b>	<b>287,210</b>	<b>294,492</b>	<b>297,101</b>	<b>293,462</b>	<b>289,398</b>	<b>292,656</b>	<b>334,356</b>	<b>368,553</b>	<b>384,559</b>	<b>388,220</b>	
<b>Total services provided</b>	Male (all)	265,968	342,816	591,863	686,581	749,679	795,495	889,059	970,958	994,688	1,029,189	
	-of which MSM	23,275	27,712	47,247	50,546	55,955	61,322	62,899	69,860	82,813	91,701	
	Female	280,300	359,527	651,303	738,157	813,214	857,330	994,540	1,105,587	1,137,272	1,184,375	
	<b>Total</b>	<b>546,268</b>	<b>702,343</b>	<b>1,243,166</b>	<b>1,424,738</b>	<b>1,562,893</b>	<b>1,652,825</b>	<b>1,883,599</b>	<b>2,076,545</b>	<b>2,134,801</b>	<b>2,216,494</b>	

Source: HPA Centre for Infections

- data not available/applicable

\* KC60 codes were created/revised in quarter 3, 2002

† previous diagnosis of C11A or C11B treated for more than 3 months

## Supplementary Tables of Sexually Transmitted Infections in England



Code Groups
<b>New STI diagnoses</b>
Chlamydial infection (uncomplicated and complicated)
Gonorrhoea (uncomplicated and complicated)
Infectious and early latent syphilis
Genital herpes simplex (first episode)
Genital warts (first episode)
New HIV diagnosis
Non-specific genital infection (uncomplicated and complicated)
Chancroid/lymphogranuloma venereum (LGV)/Donovanosis
Molluscum contagiosum
Trichomoniasis
Scabies
Pediculus pubis
<b>Other STI diagnoses</b>
Congenital and other acquired syphilis
Recurrent genital herpes simplex
Recurrent and re-registered genital warts
Subsequent HIV presentations (including AIDS)
Ophthalmia neonatorum (chlamydial or gonococcal)
Epidemiological treatment of suspected STIs (syphilis, chlamydia, gonorrhoea, non-specific genital infection)
<b>Other diagnoses made at GUM clinics</b>
Viral hepatitis B
Viral hepatitis C
Vaginitis and balanitis (including epidemiological treatment)
Anogenital candidiasis (including epidemiological treatment)
Urinary tract infection
Cervical abnormalities
Other conditions requiring treatment at a GUM clinic
<b>Services provided</b>
HIV antibody test
Sexual health screen
Hepatitis B vaccination
Contraception (excluding condom provision)
Other episode not requiring treatment